Price Chart

Executive Summary

AtaiBeckley Inc. announced the peer-reviewed publication of positive Phase 2a data for its intranasal therapy BPL-003 in treatment-resistant depression (TRD), showing rapid and sustained symptom reduction after a single dose. The results support the planned initiation of Phase 3 trials in Q2 2026, following a successful FDA End-of-Phase 2 meeting. The drug has Breakthrough Therapy designation and demonstrated strong efficacy and tolerability in a small cohort.

Key Facts

• Phase 2a Cohort 1 data published in Journal of Psychopharmacology: 12 patients with TRD received a single 10 mg intranasal dose of BPL-003.
• Mean MADRS score reduction of 12.6 points by Day 2, sustained to Day 85 (mean score 14.5).
• 54.5% response rate (≥50% MADRS reduction) and 63.6% remission rate (MADRS ≤10) observed over 12 weeks.
• SHAPS scores improved from 8.4 to 1.5, indicating resolution of anhedonia.
• No serious adverse events; treatment well tolerated with only mild-to-moderate transient side effects.
• FDA Breakthrough Therapy designation granted for BPL-003 in TRD.
• Phase 3 program on track to initiate in Q2 2026.

Financial Impact

Non-dilutive, near-term value inflection expected ahead of Phase 3 initiation. No direct revenue or EPS impact yet, but de-risks clinical pathway for BPL-003.

Risk Factors

• Small sample size (n=12) limits generalizability.
• Open-label design introduces bias; placebo-controlled Phase 3 data needed.
• Development risk remains high for a novel psychedelic-based therapy.
• Future dilution likely as Phase 3 funding approaches.

Market Snapshot

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

US Market Status

Related Tickers